Video

What Kids Wear Could Determine How Much Exercise They Get

Few College Students Have Received the H1N1 Vaccine

Night Lights Could Lead to Depression

Cervarix Has Been Approved by the FDA

The FDA Is Studying the Effects of Lasik Surgery

Painkillers Can Dull the Effects of Childhood Vaccines

Childbirth May Becoming More Complicated

Botox Sponges Might Help Nose Allergies

The FDA Advises on How to Properly Dispose of Medicine

A French Study Shows Cell Phones Do Not Affect Humans

MRIs May Lead to More Back Surgery

Your More Likely to Wash Your Hands If Someone's Watching

Co-Sleeping Is a Leading Cause of SIDS

Night Shifts Don't Have a Major Effect On Surgeons

Exercise May Counter Fatigue from Chemotherapy

Drug Improves Mobility in Some MS Patients

Posted on 02/27/2009, 09:00
By -- Robert Preidt

Fampridine may boost walking ability, but some risks tied to dose strength, study says

FRIDAY, Feb. 27 (HealthDay News) -- The drug fampridine improves walking ability in some people with multiple sclerosis.

In a phase III study that included 301 patients, aged 18 to 70, the participants were randomly assigned to receive either 10 milligrams of fampridine or a placebo twice a day for 14 weeks. The patients' walking speed was assessed after two weeks, six weeks, 10 weeks and 14 weeks.

The number of timed walk responders -- those who achieved a faster walking speed in at least three of the four assessments while on treatment compared to when they weren't on treatment -- was 78 out of 224 (35 percent) in the fampridine group and six out of 72 (8 percent) in the placebo group. The patients in the fampridine group also showed greater improvement in leg strength.

Eleven patients (5 percent) in the fampridine group had to withdraw from the study due to adverse events, but only two serious adverse events (focal seizure and severe anxiety) were considered to be connected with the drug, according to Andrew Goodman, of the University of Rochester Medical Center, and colleagues. But they added that the risk of seizure noted in previous studies seems to increase in a dose-dependent way with fampridine.

"Treatment with fampridine produces clinically meaningful improvement in walking ability in some people with multiple sclerosis, irrespective of disease course type or concomitant treatment with immunomodulators," the researchers concluded.

The study was published in this week's edition of The Lancet.

MS patients suffer a progressive decline in mobility, but there are few treatment options available to complement physiotherapy. While it has been suggested that fampridine may improve visual function, strength, walking ability, fatigue and endurance in MS patients, there are questions about the drug's efficacy and safety.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.

SOURCE: The Lancet, news release, Feb. 27, 2009

More news in Multiple Sclerosis...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.0 / 5 (116 votes)